Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | TSHR | P16473 | 6/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883438 | 0.97 | ALDH1A1 (0.65) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL1646005 | 0.87 | ALDH1A1 (0.52) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL31633568 | 0.87 | ALDH1A1 (0.52) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL10788361 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL65261 | 0.78 | ALDH1A1 (1.00) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL11451460 | 0.76 | ALDH1A1 (0.58) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL27475337 | 0.76 | ALDH1A1 (0.58) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Hydrochloric Acid SCHEMBL379126 | 0.75 | ALDH1A1 (0.92) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Hydrochloric Acid SCHEMBL379125 | 0.75 | ALDH1A1 (0.92) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Hydrochloric Acid SCHEMBL2443748 | 0.75 | ALDH1A1 (0.92) | ALDH1A1TSHRALOX15HSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171655-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-19 | — | — | US | claimed |
| EP-1927596-B9 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2013-05-15 | — | — | EP | claimed |
| EP-1927596-B1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-08-01 | — | — | EP | claimed |
| EP-2420507-A1 | Diphosphine ligand and transition metal complex using the same | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | claimed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | claimed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | claimed |
| CN-101312984-B | Diphosphine ligand and transition metal complex using same | TAKEDA PHARMACEUTICAL | 2015-05-27 | — | — | CN | disclosed |
| US-8981147-B2 | Diphosphine ligand and transition metal complex using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140171655-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-1927596-B9 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2013-05-15 | — | — | EP | disclosed |
| EP-1927596-B1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-2420507-A1 | Diphosphine ligand and transition metal complex using the same | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-8053604-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-08 | — | — | US | disclosed |
| EP-1452537-B1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-05 | — | — | EP | disclosed |
| CN-101312984-A | Diphosphine ligand and transition metal complex using same | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-11-26 | — | — | CN | disclosed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | SPERA PHARMA, INC. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1452537-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | BACE1, H1-10, PRMT1 | ALDH1A1 2206/4885TSHR 1972/4885ALOX15 3860/4885 |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | H1-10, ITPA, RER1 | ALDH1A1 4580/4885TSHR 1089/4885ALOX15 4788/4885 |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | MVD, C5, C1S | ALDH1A1 1165/4885TSHR 1507/4885ALOX15 1679/4885 |
| US-20140171655-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | MVD, C5, C1S | ALDH1A1 1165/4885TSHR 1507/4885ALOX15 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.